2924
T3D2882
Isoflurane
Isoflurane is only found in individuals that have used or taken this drug. It is a stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem]Isoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Isoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. Also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Isoflurane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor.
26675-46-7
3763
C3H2ClF5O
183.971430
48-48.5°C
48.5°C
4470 mg/L (at 37°C)
Inhalation
Isoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Isoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. Also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Isoflurane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor.
Minimal
LC50=15300 ppm/3 hrs (inhalation by rat)
No indication of carcinogenicity to humans (not listed by IARC).
For induction and maintenance of general anesthesia.
May lead to cardiac arrhythmias and death (Rarely). In susceptible individuals, Isoflurane anesthesia may trigger a skeletal muscle hypermetabolic state leading to high oxygen demand and the clinical syndrome known as malignant hyperthermia. The syndrome includes nonspecific features such as muscle rigidity, tachycardia, tachypnea, cyanosis, arrhythmias, and unstable blood pressure.(L1471)
The predicted effects of acute overexposure by inhalation of Isoflurane, USP include headache, dizziness or (in extreme cases) unconsciousness. (L1471)
Stop drug administration, establish a clear airway, and initiate assisted or controlled ventilation with pure oxygen. (L1712)
2009-07-21T20:27:35Z
2014-12-24T20:25:52Z
Isoflurane
C07518
6015
Isoflurane
DB00753
true
FC(F)OC(Cl)C(F)(F)F
C3H2ClF5O
InChI=1/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H
InChIKey=PIWKPBJCKXDKJR-UHFFFAOYNA-N
184.492
183.971433418
Exogenous
Liquid
2.06
HMDB14891
CHEMBL1256
3631
<p>Leonid A. Rozov, Fernando Quiroz, Gerald G. Vernice, “Preparation of isoflurane.” U.S. Patent US5416244, issued March, 1973.</p>